Podcasts about Astrup

Langrenter opp overalt // Astrup forutså renteuro // Hegnar om matpriser Hosted on Acast. See acast.com/privacy for more information.

Hvorfor opfører Thomas M sig som månedens medarbejder i Danske Bank?Siden hvornår er saunagus på fødderne blevet en ting?Hvorfor kan INGEN tælle til 3?  Hvorfor skal voksne mennesker stå og kramme foran en anden flok mennesker? Hvad er det Nadia kan med de albuer? Vi har så mange spørgsmål - og vi forsøger at besvare dem lige her i din yndlingspodcast! Følg os - altså hvis du har insta: @giftitv_podcast Dine værter er Freia Sands og Martin Martensen-LarsenVil du skælde os ud, heppe eller spørge.. Skriv til vores instagram på @giftitv_podcast og giv os 55 stjerner (eller nul, hvis du virkelig mener det) inde i Apple - så blir vi ret glade, for begge dele. 

Hvis Fejø Plantage omlagde sig selv til en swingerklub, ville det lyde nogenlunde som denne uges episode af Kærlighed hvor Kragerne vender. Aldrig har folk talt så perverst over en æblemostpresserdims - det sgu da lige være dengang nogen lavede en plakat af en agurk der boller og opfordrede Danmarks befolkning til "6 om dagen" Men Freja kan lide det og hviner da Jonas sprøjter på hende. Med æblerne. Og italesætter det. Og Jonas blir blød i knæene da han opdager hvor sindsygt meget wifepotentiale der ligger i Freja fra Vejle når hun sådan håndterer de æbler med de bare næver. Før det bliver alt for hedt, sku vi også lige en tur til Danmarks New York, Astrup, der med sine 276 indbyggere må siges at være noget af en metropol. Og det virker da også som en sand babe-magnet da Vestjyllands ambassadør viser rundt på hovedgaden i Astrup. Her bor farmor og farfor og hov.. er det en børnehave lige derovre hvor vores afkom kan blive afleveret? Hallo den by kan ALT! Hos Thomas G er der gang i noget leg med harpiks. Det går ikke videre godt. Følg os - altså hvis du har insta: @giftitv_podcas Dine værter er Freia Sands og Martin Martensen-LarsenVil du skælde os ud, heppe eller spørge.. Skriv til vores instagram på @giftitv_podcast og giv os 55 stjerner (eller nul, hvis du virkelig mener det) inde i Apple - så blir vi ret glade, for begge dele. 

There are so many weightloss myths out there that it is so easy to become distracted and disillusioned. In this episode, I draw on the advice of many of the scientists and doctors I have interviewed on this channel about nutrition, metabolism and weightloss, and I detail 9 commonly held misconceptions about weightloss which is hampering peoples' weight loss goals .For example, I examine if skipping breakfast really helps you lose weight and I analyse if consuming fat can actually help you lose weight. Throughout this video I use science and research to flesh out each argument.You'll find all the references to the research papers I mention below :Westerterp, K. R. (2004). “Diet-induced thermogenesis.” Journal of Nutrition.Stote, K. S., et al. (2007). “Meal frequency and energy balance.” British Journal of Nutrition.Mozaffarian, D., et al. (2006). “Trans fatty acids and cardiovascular disease.”Circulation. Bazzano, L. A., et al. (2010). “Comparison of low-fat and low-carbohydrate diets for weight loss.”Annals of Internal Medicine. Estruch, R., et al. (2018). “Mediterranean diet and cardiovascular health.” New England Journal of Medicine.Sutton, E. F., et al. (2018). “Meal timing, circadian rhythms, and metabolic health.” Cell Metabolism.Almoosawi, S., et al. (2013). “Late-night eating and its metabolic consequences.”Obesity Reviews. Garaulet, M., et al. (2013). “Timing of food intake and obesity: A review.” International Journal of Obesity.Betts, J. A., et al. (2014). “Impact of breakfast on daily energy intake and weight regulation.” British Journal of Nutrition. Jakubowicz, D., et al. (2013). “The effect of breakfast on weight regulation.” Obesity. Farshchi, H. R., et al. (2005). “Regular meal patterns are associated with better food choices.” American Journal of Clinical Nutrition. Ludwig, D. S. (2002).“The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease.” New England Journal of Medicine. Hall, K. D., et al. (2015). “Energy balance and weight loss: The role of diet composition.” American Journal of Clinical Nutrition. Pereira, M. A., et al. (2002).“Effect of fat intake on satiety and energy balance.” American Journal of Clinical Nutrition. Slavin, J., & Lloyd, B. (2012). “Health benefits of fruits and vegetables.”Nutrition Journal. He, F. J., et al. (2007). “Fruit and vegetable intake and risk of cardiovascular disease.” British Journal of Nutrition. Astrup, A., et al.(2011). “The role of diet in weight loss and maintenance.” Obesity Reviews. Mann, T., et al. (2007). “Medically supervised weight loss: A review of crash diets.” The New England Journal of Medicine. Heymsfield, S. B., et al. (2014). “Mechanisms of weight regain after rapid weight loss.” Obesity Reviews. Hill, J. O., et al.(2012). “Sustainable weight loss: Lessons from the long term.” Journal of the American Dietetic Association. Longo, V. D., & Panda, S. (2016).“Fasting, circadian rhythms, and time-restricted feeding in healthy lifespan.” Cell Metabolism. Tinsley, G. M., & La Bounty, P. M. (2015). The dangers of high carbohyrate foods : https://www.youtube.com/playlist?list=PLSKlhyEANfi8hZFoFoJun_lLhULcYg5JWWeightloss series : https://www.youtube.com/playlist?list=PLSKlhyEANfi-pO3W2hejnDUsgMQ9GPvpZThe health benefits fo exercise : https://www.youtube.com/playlist?list=PLSKlhyEANfi_vM1nbpcV-PlvWjSZ872ECListen to all previous podcast episodes of the Happy Habit Podcast via these podcast platforms :Apple Podcasts https://podcasts.apple.com/ie/podcast/happy-habit-podcastAmazon https://www.amazon.com/Happy-Habit-Podcast/dp/B08K5887J8Amazon music : https://music.amazon.com/podcasts/670836c2-ea4c-4a23-a67d-a54dd804ef61/happy-habit-podcastSpotify https://https://open.spotify.com/show/2VKIhQK6mYTzLCO8haUoRdFollow the Happy Habit Podcast Website: https://happyhabitpodcast.wordpress.com/Music used is Purple planet Music crediit goes to them

TakeawaysCarnivore Ernährung wird als therapeutisches Werkzeug betrachtet.Fleisch hat eine zentrale Rolle in der menschlichen Evolution gespielt.Morphologische Anpassungen des Menschen unterstützen eine fleischbasierte Ernährung.Die Nährstoffdichte in tierischen Lebensmitteln ist höher als in pflanzlichen.Es gibt keine dokumentierten veganen Jägersammlergesellschaften.Gesättigte Fette sind in ihrer natürlichen Matrix unbedenklich.Die Inuit und andere Jägersammlergesellschaften zeigen, dass eine fleischlastige Ernährung gesund sein kann.Evidenzbasierte Ansätze sind entscheidend für die Ernährung.Kapitel00:00 - Einleitung: Ist carnivore Ernährung wirklich Unsinn? 01:00 - Fleisch und Evolution: Die Rolle der Steinwerkzeuge 02:50 - Australopithecus: Erste Hinweise auf Fleischkonsum 04:20 - Eiszeit und große Jäger: Homo erectus und die Megafauna 06:30 - Übergang zur Sesshaftigkeit: Ein langsamer Prozess 09:00 - Unsere Anatomie: Zähne, Magen und Verdauungstrakt 11:30 - Nährstoffe aus tierischer Nahrung: Hohe Dichte und Bioverfügbarkeit 13:50 - Antioxidantien, Ketose und entzündungsarme Ernährung 16:10 - Fehlende große Studien? Evidenz aus Fallstudien und Evolution 18:30 - Fazit: Fleisch als zentrales Nahrungsmittel der Menschheit Original Artikel: Iss Dich Gesund / 01-2025/ Seite 79 "Riedls Aufreger"Literaturquellen:Heinzelin, Jean de, et al. "Environment and behavior of 2.5-million-year-old Bouri hominids." Science 284.5414 (1999): 625-629.Richards, Michael P., and Erik Trinkaus. "Isotopic evidence for the diets of European Neanderthals and early modern humans." Proceedings of the National Academy of Sciences 106.38 (2009): 16034-16039.Mann, Neil. "Meat in the human diet: An anthropological perspective." Nutrition & Dietetics 64 (2007): S102-S107.Fujimori, Shunji. "Gastric acid level of humans must decrease in the future."World Journal of Gastroenterology 26.43 (2020): 6706Blumenschine, Robert J., et al. "Characteristics of an early hominid scavenging niche [and comments and reply]." Current anthropology 28.4 (1987): 383-407.Aiello, Leslie C., and Peter Wheeler. "The expensive-tissue hypothesis: the brain and the digestive system in human and primate evolution." Current anthropology (1995): 199-221.Gurven, Michael, and Hillard Kaplan. "Longevity among hunter‐gatherers: a cross‐cultural examination." Population and Development review 33.2 (2007): 321-365.Cordain, Loren, et al. "Plant-animal subsistence ratios and macronutrient energy estimations in worldwide hunter-gatherer diets." The American journal of clinical nutrition 71.3 (2000): 682-692.Lescinsky, Haley, et al. "Health effects associated with consumption of unprocessed red meat: a Burden of Proof study." Nature Medicine 28.10 (2022): 2075-2082.Astrup, Arne, et al. "Saturated fats and health: a reassessment and proposal for food-based recommendations: JACC state-of-the-art review." Journal of the American College of Cardiology 76.7 (2020): 844-857.Yamada, Satoru, et al. "Saturated Fat Restriction for Cardiovascular Disease Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Trials." (2024).Beasley, DeAnna E., et al. "The evolution of stomach acidity and its relevance to the human microbiome." PloS one 10.7 (2015): e0134116.Norwitz, Nicholas G., and Adrian Soto-Mota. "Case report: Carnivore–ketogenic diet for the treatment of inflammatory bowel disease: a case series of 10 patients." Frontiers in Nutrition 11 (2024): 1467475.Calabrese, Lori, Rachel Frase, and Mariam Ghaloo. "Complete remission of depression and anxiety using a ketogenic diet: case series." Frontiers in Nutrition 11 (2024): 1396685.Cordain, Loren, et al. "The paradoxical nature of hunter-gatherer diets: meat-based, yet non-atherogenic." European journal of clinical nutrition 56.1 (2002): S42-S52.Beal, Ty, and Flaminia Ortenzi. "Priority micronutrient density in foods." Frontiers in nutrition 9 (2022): 806566.Ben‐Dor, Miki, Raphael Sirtoli, and Ran Barkai. "The evolution of the human trophic level during the Pleistocene." American journal of physical anthropology 175 (2021): 27-56. Bitte beachte auch immer den aktuellen "Haftungsausschluss (Disclaimer) und allgemeiner Hinweis zu medizinischen Themen" auf meiner Webseite.

Ce dernier tournoi de l'année 2024 a tenu toutes ses promesses, avec notamment trois titres chinois à domicile. Pas de Chen/Jia ou Liu/Tan, surprises en demi-finale du double dames, mais Shi Yuqi et Wang Zhiyi sur les tableaux de simples. Zheng/Huang s'imposent en mixte pour leur dernier tournoi commun, en battant Chen/Toh dans une finale dantesque. En double hommes, les danois Astrup/Rasmussen ont décroché le meilleur titre de leur carrière, juste récompense de leur très bonne saison. Chapitres :0:00 - Introduction et simple hommes18:16 - Simple dames30:18 - Double hommes46:56 - Double dames55:26 - Double mixte1:12:40 - Conclusion Participer à "On devine vos classements" : https://forms.gle/pc4PXfhQuou9XpCTA Où nous retrouver : https://linktr.ee/21shuttleRejoindre notre serveur Discord : https://discord.gg/fKmkvQ2RmQ Crédit photo : Sylvain Nalet

Afsnit 642 Jacob Astrup. Jacob er direktør for Mandecentret. Mandecentret er et tilbud til mænd der står i en situation der gør livet svært som f.eks. at blive udsat for uacceptabel adfærd i sit parforhold. Derfor snakker vi meget om mænds problemstillinger i samfundet og forhold, manderollen i fiktion og i virkeligheden og meget, meget mere. Jacob er lige så vidende som han er formidlende, hvilket du kommer til at opleve i dagens afsnit.Gå fornøjelse, Christian.

I ukas #pengepodden får vi et eksklusivt innblikk i tankene til Morten Astrup, en anerkjent investor med en lang karriere bak seg. Morten, som har vært involvert i aksjemarkedet siden han var 13 år, deler sine erfaringer om markedets svingninger og hvordan han har navigert gjennom dem.Agenda:(01:17) - Mortens reise som investor(19:55) - Utsikter og investeringsporteføljeDenne podcasten skal anses som markedsføringsmateriell, og innholdet må ikke oppfattes som en investeringsanbefaling. Podcasten er kun ment til informasjonsformål og generell spareveiledning. Nordnet tar ikke ansvar for eventuelle tap som måtte oppstå ved bruk av informasjonen i denne podcasten. Les mer på Nordnet.no Hosted on Acast. See acast.com/privacy for more information.

Frontalangrep på XXL // Hyller økte Finn-priser // Hegnar om statsbudsjettet Hosted on Acast. See acast.com/privacy for more information.

I denne episoden har Marius Brun Haugen med seg analytiker Håkon Astrup i studio. Det har vært store bevegelser i den norske banksektoren den siste tiden. Skjer det nå så store endringer at vi må begynne å tenke på en slags «ny normal» for norske banker? I tillegg er Håkon og resten av analyseteamet i DNB Markets ute med resultatene fra den årlige bankundersøkelsen. Rapporten inkluderer også godbiter som sektorsyn og topp anbefalinger. Alt dette får du høre mer om dagens episode. Episoden ble spilt inn 2. september 2024.Produsent: Kim A. Farago, DNB Wealth Management. Hosted on Acast. See acast.com/privacy for more information.

Hamish Brown nærmer sig med hastige skridt DP World Tour. En andenplads i Skotland sendte danskeren helt op på tredjepladsen på Challenge Tourens rangliste i en turnering, hvor hele tre danskere endte i top 10. Lydia Ko tog det sidste skridt ind i LPGAs Hall of Fame, da hun sikrede sig guldmedaljen i Paris. Den kom efter en spændende OL-turnering, hvor medaljerne skiftede hænder flere gange undervejs, og hvor de danske deltagere aldrig for alvor blandede sig. Vi taler med Flemming Astrup, manden bag Danish Golf Championship, her ni dage før det går løs ved på Lübker Golf Resort. Hvad kan vi forvente os af den nye hjemmebane, hvad skal vi se frem til og hvad har udfordringerne været? Golf Showet er produceret af Qvortrup Media i samarbejde med https://www.golfexperten.dk og https://shapingnewtomorrow.dk. Book din Titleist GT driver-fitting på https://www.titleist.eu/fitting Køb billetter til Danish Golf Championship på https://danish.golf

Oljeselskap i pengenød // Rabatt på 16,5 mill. på Tjøme // Hegnar om Pollestad Hosted on Acast. See acast.com/privacy for more information.

¿Quieres saber cómo acelerar tu metabolismo y quemar calorías sin esfuerzo? En este podcast, te presentamos 10 alimentos que te ayudarán a aumentar tu tasa metabólica y quemar más calorías incluso en reposo. Descubre cómo incorporar estos superalimentos en tu dieta diaria y disfruta de sus increíbles beneficios para la salud y la pérdida de peso.

Et fulltallig panel er til stede i episoden som har følgende innhold: 02:02 Siste ukers handler med Sacam, Akh, Acc, Hav, Zaptec, Nol, Fing, DJT, Gsf, Ddril m fl 12:50 Siste ukers emisjoner: Stordeal og emisjon i Dof, Edda Wind, Norbit, Ventura og E&P bonds til høye renter 23:30: Investorene stirret på Marine Traffic mens Dolphinriggen flyktet fra Nigeria 29:55 US/UK-valg og «Trump-aksjer» 41:55 Rapporteringssesongen innledes med 2X fly profit warnings (Norse og Norwegian) 44:37 Huddly CEO går på dagen mens strategisk gjennomgang pågår 45:38 Rakettoppgang etterfulgt av crash og svanesang i EAM Solar 52:05 Kollaps i Africa Energy, politisk risiko, avkastningskrav og stranded assets 58:15 Blackout-periode 1:00:22 En oppfordring fra Farsund 1:02:04 Traderen – kommende ukes favoritter og obs'er med bla Ntg, Osun og Acc 1:09:30 Jallakongen: Fingerprint Cards, Norse, SAS 1:14:23 Nedsalg i Beerenberg – rumpekjørt trader, dement raider og Apolloprosjekt. 1:20:33 Raideren: Nol, Acc med rapport, Astrup-filosofi til etterfølgelse, Nas og Carasent.

Le 24 avril, dans l'épisode #99, j'avais abordé 5 mythes sur la caféine. Je vous avais dit qu'il y en avait plus que 5, mais que le podcast serait trop long. Cette semaine, j'ai décidé de poursuivre sur ce sujet en vous amenant 1 seul point pour une partie #2. Ce mythe nécessite que j'approfondisse davantage, donc, encore une fois, le podcast serait trop long si je couvrais tous les mythes restants. Voici la question que nous allons examiner ensemble : Est-ce que la caféine diminue le poids et le gras ? Références = Antonio J, et al. Common questions and misconceptions about caffeine supplementation: what does the scientific evidence really show?. (2024) 1. Augmentation du Métabolisme de Base de 3 à 11% Comparison of changes in energy expenditure and body composition after caffeine consumption. Astrup, A., et al. 1995. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. Bracco, D., et al. 1995. 2. Augmentation du NEAT Influence of caffeine on the resting metabolic rate of exercise-trained and inactive individuals. Arciero, P.J., et al. 1995. The acute effects of thermogenic fitness drink formulas containing caffeine on resting metabolic rate. Campbell, B.I., et al. 2020. 3. Tolérance à la Caféine et Diminution des Effets à Long Terme Development of tolerance to the metabolic effects of caffeine. Robertson, D., et al. 1981. Caffeine tolerance and its effects on metabolism and thermogenesis. James, J.E., et al. 2004. 4. Impact de la Caféine sur le Sommeil The effects of caffeine on sleep: a review of the literature. Roehrs, T., et al. 2008. Chronic effects of caffeine on sleep and daytime fatigue. Drake, C.L., et al. 2013. 5. Effet de la Caféine sur l'Appétit Caffeine and appetite regulation: a review. Westerterp-Plantenga, M.S., et al. 2005. Effect of caffeine on appetite and energy intake. Martins, C., et al. 2007. 6. Effet de la Caféine sur l'Intensité, la Force et l'Endurance à l'Entraînement Caffeine and exercise: metabolism, endurance and performance. Graham, T.E., et al. 2001. The acute effects of a caffeine-containing supplement on strength and muscular endurance. Astorino, T.A., et al. 2007. Je pourrais continuer à vous citer beaucoup d'études, mais je serais là jusqu'à demain matin, lol. Je pense que vous en avez assez pour approfondir vos recherches si vous le souhaitez !

Send us a Text Message.When you think of family vacations, you might envision crowded theme parks or beachside resorts. But what if the journey itself became a communal adventure? Joining us on the show is Nikolaj Astrup Madsen, one of the founders behind the fascinating Traveling Village concept. He unfolds the story of 20 families who traded the conventional holiday for a four-month exploration of Vietnam, Thailand, and Japan, not as mere tourists but as a village on the move. Nikolaj walks us through the labyrinth of planning an expedition, the intricate social tapestry of life on the road, and the unforgettable impact of deep cultural immersion while preserving a collective identity.Twenty families traveled together for four months. Every family had its own place but a community living room. Kids learned through play and exploration, and their parents helped each other with co-living, communal meals, and the adventure of a lifetime.As we unpack the post-travel musings, Nikolaj shares the bittersweet reality of returning to everyday life after such an intense group experience. The dialogue pivots to the subtle yet significant nuances of how a large group navigates interactions with locals and impacts children's social adaptability. The Traveling Village becomes more than a simple group trip—it's a transformative lifestyle that has etched a lasting influence on its members, igniting aspirations for future communal adventures. Through Nikolaj's captivating recount of this unique travel experiment, tune in to discover the life-altering potential of intentional community living.

Ukens ferske tall for prisveksten i USA tilsier at den amerikanske sentralbanken på langt nær kan erklære kampen mot inflasjonen som vunnet og det spøker stadig mer for rentekutt i løpet av sommeren. Hva betyr dette for aksjer, den norske kronen og Norges Bank? Det ser Marius Brun Haugen nærmere på i dagens episode sammen med aksjestrateg Paul Harper og analytiker Håkon Astrup. De diskuterer også de generelle utsiktene for norske bank- og forsikringsaksjer. Episoden ble spilt inn torsdag 11. april klokken 14:30.Produsent: Kim A. Farago, DNB Wealth Management. Hosted on Acast. See acast.com/privacy for more information.

LoveBabz LoveTalk: Composer Martin Hebel and Margaret Astrup by WNHH Community Radio

Polarpioneren Eivind AstrupChristianiamannen Eivind Astrup deltok i to ekspedisjoner til Grønland, ledet av amerikaneren Robert E. Peary. Eivind Astrup var superkjendis i sin tid, men er i dag lite kjent. I den første av de to ekspedisjonene med Peary kartla de Grønlands nord- og østlige deler, ikke minst takket være Astrups innsats. Han var den første som kombinerte bruk av ski med hundesleder, en kombinasjon som med hell også ble brukt av Roald Amundsen noen år senere da Sydpolen ble beseiret.Kartla GrønlandDen andre ekspedisjonen til Grønland ble langt på vei ødelagt av bedervet pemmikan, og både Astrup og flere andre av deltagerne ble syke. Likevel gjennomførte Eivind Astrup og vennen Kolotengva en ekspedisjon for å kartlegge nordsiden av Melville Bay – det eneste av vitenskapelig verdi fra ekspedisjonen. Eivind Astrup har åpenbart følt en nær tilhørighet til de grønlandske inuittene, og han både omtalte og skrev om dem med stor respekt. Han samlet også inn et stort etnografisk materiale for å dokumentere deres levevis og kultur.LandesorgDet var i mange år stor usikkerhet rundt dødsfallet til Eivind Astrup. Han reiste til Folldal julen 1895, og selv om han ble funnet død første en måned senere, er det antatt at han skjøt seg selv med en pistol tredje juledag på Hjerkinn. Det vakte landesorg da Astrups død ble kjent, og flere tusen mennesker fulgte kista til Vår frelsers gravlund i Oslo.Podkasten Villmarksliv – Påskespesial 2024I påsken 2024 kan du høre følgende episoder fra Podkasten Villmarksliv:28. mars 2024: Hans Børli29. mars 2024: Jens Munk30. mars 2024: Eivind Astrup31. mars 2024: Tryggve GranLytt gjerne til episoden seriene Norske eventyrere og eventyrlige historier fra påsken 2022 og påsken 2023.Hør også: Hjalmar Dale - læremesteren til Helge IngstadBli gjerne med i vår nye Facebook-gruppe for Podkasten Villmarksliv.Støtt Podkasten Villmarksliv ved å abonner på Villmarksliv, Jakt eller Alt om fiske. (Foto: Daniel Georg Nyblin/Nasjonalbiblioteket) Hosted on Acast. See acast.com/privacy for more information.

Danish Golf Championship, den danske DP World Tour-turnering, kommer til Furesø Golfklub. Det har vi talt med turnerings-ejer og arrangør Flemming Astrup om, og den snak kan du høre til sidst i dagens afsnit (1:09:50) Verdens bedste golfspiller hedder Scottie Scheffler. Den 27-årige amerikaner vandt for anden uge i træk, denne gang med hold i nakken, og han blev den første til at forsvare en sejr ved The Players Championship. Vi følger op på hvordan det gik danskerne på Challenge Tour i Indien, en ny dansker på vej frem i USA, en dramatisk afslutning på NEXT Golf Tour, og så varmer vi op til denne uge hvor DP World Tour er tilbage i Singapore med seks danskere til start. Golf Showet er produceret af Qvortrup Media i samarbejde med https://www.golfexperten.dk og https://shapingnewtomorrow.dk. Brug koden HFGOLF på hellofresh.dk og spar op til 1.199 kroner på dine fem første måltidskasser.

Morten Astrup is one of the most active investors in energy and shipping markets in the Nordics, and is currently the new chairman of Hunter Group. Morten Astrup founded Storm Capital Management in 2006 and has experience from a wide range of sectors and strategies. He is the executive Chairman of Storm Bond Fund and has been one of the largest investors in the fund since inception.00:00 - Hunter Group06:00 - Tanker Markets Ahead11:30 - Oil Service Opportunities15:30 - DOF And How To Find Great Companies17:55 - Offshore Wind And Nuclear Energy21:00 - Gram Car Carriers And The RoRo Market Ahead24:35 - Inflation, War Economy And Interest Rates27:30 - US Election And Recession Fear29:00 - The Five Risks In High Yield Investing35:30 - Quick Fire (India, Saudi, Stocks, Bitcoin, Travel Destinations)This is the third time Morten joins the Vonheim podcast, the two previous ones have been recorded in Norwegian. Let us know what you think about the episode, and share it with your network.You can follow Morten Astrup on LinkedIn. LinkedIn ProfilePartnership, recruitment & Ad enquiries?For business and partnerships enquiries email christopher@bynorthernnorway.com or use the contact form at www.christophervonheim.comFollow Vonheim on X and YouTube:YouTube: Christopher VonheimX / Twitter: @chrisvonheimDisclaimerAll opinions expressed by Christopher Vonheim or his guests on this show are only their opinions and do not reflect the opinions of Vonheim. You should not treat any opinion expressed by Christopher Vonheim as a specific reason to invest or follow a particular strategy, but only as an expression of his opinion. This Show is for informational purposes only. Hosted on Acast. See acast.com/privacy for more information.

Blanda drops - mangfoldet gir mange favoritter. Hør episoden i appen NRK Radio

Julekaker i januar, eller nye forsetter? Hør episoden i appen NRK Radio

Å ta en snarvei, kan også være et modig valg. Hør episoden i appen NRK Radio

Ingen omveier, men en mulighet til å snu. Hør episoden i appen NRK Radio

I denne episoden har Marius Brun Haugen med seg analytiker Håkon Astrup som er spesialist på finanssektoren og analysesjef Alexander Aukner som er spesialist på sjømatsektoren. Begge er en del av analyseteamet til DNB Markets som flere år på rad har blitt kåret til Norges beste analyse- og meglerhus. I denne episoden får du blant annet høre mer om hvordan de vurderer utsiktene for sine respektive sektorer.Episoden ble spilt inn 15. desember 2023. Dette er del 5 av 5 i en miniserie om utsiktene for 2024.Produsent: Kim A. Farago, DNB Wealth Management Hosted on Acast. See acast.com/privacy for more information.

Vold i parforhold er desværre ikke en sjældenhed, og alt imens der er blevet sat mere lys på vold mod kvinder i parforhold, så har der været mindre fokus på vold mod mænd i parforholdet.Det vil vi i denne episode gerne lave om på, da vi ønsker at bidrage til aftabuiseringen af vold mod mænd og ikke mindst sætte lys på, hvordan vold mod mænd typisk ser ud, hvordan vi kan opdage at en mand er udsat for vold og ikke mindst, hvordan vi kan hjælpe som medmennesker og pårørende. 

Speaking at the cooperative's annual meeting, American Crystal president Tom Astrup said everything lined up for growers this year. The cooperative is forecasting a record payday for growers, but Astrup said operating costs are also rising.That story and more in today's evening update from MPR News. Hosted by Jacob Aloi. Music by Gary Meister.

Der ehemalige Keyboarder der Band ECHT über die Geschichte der Band. Unser Partner in dieser Woche ist das Mercado. Foto:

B.T.-journalist Peter Astrup fik anden bølge af Jeppe Kofods gamle sex-skandale til at rulle igen i 2020 med et epokegørende interview. Nu fortæller han, hvad der skete bag kulisserne i Fonsecas sag og sammenligner den med Jeppe Kofods fra 2008. Vi har besøg af Astrup. Og så snakker vi selvfølgelig om rokaden - er Venstre helt på røven?Værter: Anna Thygesen og Sanne FahnøeGæst: Peter Astrup, B.T.Producer: Marcus Eklund

Den lille overnattingsgjesten hadde et uvanlig ønske før han skulle legge seg. Pernille Astrup er studentprest - og velvillig barnevakt. Hør episoden i appen NRK Radio

"Gjør det, gjør det, gjennomfør det!" Da håndballjentene ville høre velsignelsen, ble hun flau. Studentprest Pernille Astrup forteller. Hør episoden i appen NRK Radio

Exceptionnellement délocalisés à Rennes, ces Internationaux de France 2023 ont vu Margot Lambert et Anne Tran montrer de belles promesses, et atteindre les quarts de finale. Thom Gicquel et Delphine Delrue ont déçu en ne passant pas le premier tour, tandis que Toma Jr. Popov et Arnaud Merkle ont chacun obtenu une belle victoire devant leur public. La Chine a encore imposé sa force avec trois titres donc celui des jeunes paires Liu/Tan et Jiang/Wei, ainsi que de Chen Yufei, solide face à Taï Tzu-ying en finale. La CBA aurait également pu s'offrir le simple hommes si Jonatan Christie n'avait pas renversé Li Shifeng a la surprise générale, tandis que Astrup et Ramussen restent sur un nuage en remportant leur premier Super 750. Chapitres :0:00 - Introduction et double mixte13:19 - Simple dames19:52 - Double dames28:37 - Simple hommes36:39 - Double hommes et conclusion Où nous retrouver : https://linktr.ee/21shuttleRejoindre notre serveur Discord : https://discord.gg/fKmkvQ2RmQ Crédit photo : Sylvain Nalet

Ce premier Arctic Open depuis le passage du tournoi finlandais en Super 500 a vu Lee Zii Jia impressionner et remporter son premier titre depuis un an . Astrup/Ramussen ont remporté leur troisième Super 500 d'affilé, tandis que la Chine a encore brillé avec trois titres. 21 Shuttle s'est également penché sur le Dutch Open avec de nombreux français engagés, mais aucune finale au compteur. Chapitres :0:00 - Introduction et double mixte9:06 - Simple dames13:38 - Simple hommes25:42 - Double dames32:22 - Double hommes40:28 - Dutch Open Où nous retrouver : https://linktr.ee/21shuttleRejoindre notre serveur Discord : https://discord.gg/fKmkvQ2RmQ Crédit photo : Sylvain Nalet

Dans ce premier Hong-Kong Open depuis quatre ans, Christo Popov a battu le 9ème mondial Loh Kean Yew pour la deuxième fois de la saison, tandis que Gicquel/Delrue continuent de remonter la pente. Alors que Jonathan Christie confirme sa belle saison, Astrup/Rasmussen ont une nouvelle fois régalé. 21 Shuttle s'est également penché sur le Belgian International et notamment le titre de Lucas Claerbout en simple hommes. Chapitres :0:00 - Introduction1:23 - Double dames6:23 - Simple dames10:58 - Double mixte19:26 - Simple hommes28:50 - Double hommes36:14 - Belgian International et conclusion Où nous retrouver : https://linktr.ee/21shuttleRejoindre notre serveur Discord : https://discord.gg/fKmkvQ2RmQ Crédit photo : Sylvain Nalet

Det bliver Lübker, der i 2024 skal lægge græs til den danske DP World Tour turnering. Made in HimmerLand er lagt i seng, og nu begynder en ny æra i Flemming Astrups virksomhed. Vi har talt med Flemming om valget af Lübker og fremtiden for turneringen. Flemming kan høres ved 14.12 og 1.23.05. Nicole Broch Estrup endte på en delt sjetteplads i et stærkt felt i Skotland. Det sikrede hende samtidig en plads i årets sidste major, AIG Women's Open, der starter på torsdag. Vi har talt med Nicole om den gode uge. Nicole kan høres ved 30.57. Hartø gjorde comeback, Morten Toft vandt, LET Access Series var i Smørum, to danskere var i top 10 på Challenge Tour, og Nicolai Højgaard tog endnu et stort skridt på vej mod et PGA Tour kort. Vi kommer omkring det hele i dagens afsnit. Golf Showet er produceret af Qvortrup Media i samarbejde med https://www.golfexperten.dk og https://shapingnewtomorrow.dk. Husk også tilbuddet fra Hello Fresh. Brug vores landing page http://hellofresh.dk/golf og få op til 1.153 kr. i rabat på dine fem første måltidskasser.

Dans un Canada Open déserté par les plus grosses stars, les Français n'auront pas réussi à se mettre en avant, la faute à des tirages au sort compliqué pour la plupart. Astrup/Rasmussen ont gagné leur deuxième tournoi consécutif, et Lakshya Sen a repris confiance, tandis que Watanabe/Higashino auront été la déception de la semaine. Dans la deuxième partie, Ewan et Benoît parlent des comptes Twitter, chaînes Youtube ou podcasts à suivre pour ne rien rater de l'actu bad ! Chapitres :00:00 - (longue) Intro03:54 - Double hommes10:18 - Double dames15:33 - Double mixte18:20 - Simple dames24:18 - Simple hommes32:39 - Les chaînes Youtube/Comptes Twitter/Podcasts à suivre Podcasts A year on tour with Wittinghus : https://open.spotify.com/show/0Z2NY2iMYEPkoSMN1muEST The Badminton Experience : https://www.youtube.com/@TheBadmintonExperience Chaînes Youtube Badminton Insight : https://www.youtube.com/@BadmintonInsight Saspiree Taerattanachai ; https://www.youtube.com/@POPORSAPSIREE Shuttle Flash : https://www.youtube.com/@ShuttleFlash Comptes Twitter Badminton Statistics : https://twitter.com/BadmintonStats Gill Clark : https://twitter.com/OmaGillClark Steen Pedersen : https://twitter.com/steenschleicher Shu (traduction) : https://twitter.com/shitouyuqi Out Of Context Badminton : https://twitter.com/nocontextbad Badminton Talk : https://twitter.com/BadmintonTalk Où nous retrouver : https://linktr.ee/21shuttleRejoindre notre serveur Discord : https://discord.gg/fKmkvQ2RmQ Crédit photo : Sylvain Nalet

Rentesmell for Norges rikeste // Investorrush i Tromsø // Hegnar om drosjeøkonomi Hosted on Acast. See acast.com/privacy for more information.

Christian Astrup fra Våler ble fylkesfører for NS i Bergen og Hordaland, men 25. oktober 1942 skjedde en veldokumentert drukningsulykke i Åndalsnes, rikspropagandasjef Gulbrand Lunde og hans kone satt i samme bil som Astrup. Del 2 av 2.Kilde: «Christian Astrup - fra Våler til Quislings bord», Oskar Aanmoen, 2018

SP 500-indeksen er offisielt ute av bear market territorium, investorsentimentet er på glad-nivåer vi ikke har sett siden slutten av 2021 og Tesla-aksjen har steget 10 strake dager på rad. Er vi i ferd med å gå fra hard landing til hard take-off?Dette diskuterer Paul Harper og Marius Brun Haugen i denne episoden. I tillegg tar de for seg renteforventningene, oljepris og den norske banksektoren. Du hører også fra oljemarkedsanalytiker Helge A. Martinsen og bankanalytiker Håkon Astrup.Sendingen ble spilt inn fredag 9. juni 2023Produsent: Kim A. Farago, DNB Wealth Management.Dersom du har ønsker om gjester vi skal invitere, temaer vi skal ta opp, eller aksjer vi skal kommentere kan du sende Marius en mail på utbyttepodden@dnb.no Hosted on Acast. See acast.com/privacy for more information.

Christian Astrup fra Våler gjorde under krigen karriere i partiet Nasjonal Samling. Astrup var i praksis også arbeidsminister i NS-regjeringens siste måneder inntil frigjøringen den 8. mai i 1945.  Del 1 av 2.Kilde: «Christian Astrup - fra Våler til Quislings bord», Oskar Aanmoen, 2018  

This is the Weight and Healthcare newsletter! If you like what you are reading, please consider subscribing and/or sharing!In part 1 we talked about a request that has been submitted for the World Health Organization (WHO) to add diet drugs (specifically GLP1 agonists like Novo Nordisk's Saxenda and Wegovy) to their list of “essential medicines.” We discussed who was making this request and the justification that they were using. In part 2 we took a deeper dive into the research that they used to try to support this request, and in this final installment, we will look at the research around efficacy, harm, and cost-effectiveness.First I'll offer a summary for each issue and then I'll give a breakdowns of the research that they cite.  Just a quick reminder that this request is asking the World Health Organization (WHO) to add these drugs to their list of “essential medications” globally.Before we get into the sections, I want to mention two overarching issues that are found throughout the entirety of this request and the studies that are used to support it.First, in general, a belief has been fomented (predominantly by those in the weight loss industry) that being higher-weight is so terrible then it's worth “throwing anything at the problem.” This leads to acceptance of poor, short-term, and/or incomplete data as “good enough” to foist recommendations onto higher-weight people, which means that part of weight stigma in healthcare is that higher-weight people are afforded less right to ethical, evidence-based medicine than thinner people.Second, is clinging to correlation (without any mechanism of causation) when it comes to weight, health, and health outcomes, including the abject failure to consider confounding variables. So throughout these studies “being higher-weight is associated with [health issue(s)]” stated uncritically in support of weight loss interventions. There is an utter failure to explore the idea that the reason for the outcome differences is not weight itself but, instead, exposure to weight stigma, weight cycling (which these medications actually perpetuate by their own admission,) and healthcare inequalities.  Issues with research supporting effectiveness, harms, and benefitsStudy Duration:This is the main issue. While there was one study that went up to 106 weeks, the vast majority of the studies are between 14 and 56 weeks. We know that these drugs can have significant, even life-threatening side effects (earning them the FDA's strongest warning.) 14-56 weeks is not not nearly enough time to capture the danger of long-term effects, or to capture long-term trends around weight loss/weight regain.Study PopulationMany of the studies included have small samples. Many have study populations are overwhelmingly white, which is a huge issue when making a global recommendations.Small effect and overlapMany of the studies show only a bit of weight loss (often 15lbs or less) and often there was overlap in weight lost between the treatment group and the placebo group. Even using the “ob*sity” construct that this request is based on, for many people, this amount of weight loss wouldn't even change their “class” of “ob*sity.”Failure to capture adverse eventsMuch of the research they use to support their claims of safety didn't actually capture individual adverse events or serious adverse events. Often they only captured subjects who reported leaving treatment due to side effects.Issues with research supporting cost effectivenessThe cost-effectiveness analyses they cite are based on Quality Adjusted Life Years (QALYs). This is a measurement of the effectiveness of a medical intervention to lengthen and/or improve patients' lives.The calculation for this is [Years of Life * Utility Value = #QALY]So if a treatment gives someone 3 extra years of life with a Health-Related Quality of Life (HRQL) score of 0.7, then the treatment is said to generate 2.1 [3 x 0.7] QALYs.This is a complicated and problematic concept that deserves its own post sometime in the future, but looking just at this request I think it's important to note that they are working on two main unproven assumptions:1. That being higher weight causes lower health-related quality of life and/or shorter life span (rather than any lower HRQL being related to experiences that higher-weight people have including weight stigma, weight cycling, healthcare inequalities et al.) 2. That this treatment induces weight loss and/or health benefits that increase the life span and/or health-related quality of life of those who take it.I don't believe either of these assumptions are proven by the material cited in the request to the WHO. Specifically, it's very possible that it's not living in a higher-weight body, but rather the experiences that higher-weight people are more likely to have (weight stigma, weight cycling, healthcare inequalities) that impact their HRQL.Further, the short-term efficacy data available (and Novo Nordisk's own admission about high rates of regain) fall far short of proving any assumptions about these drugs ability to actually improve or extend life. Further, the failure of the literature to adequately capture negative side effects of the drugs, both short and long-term, means that this calculation cannot be properly made.Incremental Cost-Effectiveness Ratio (ICER)ICER is how QALYs are turned into a monetary value. It is calculated by dividing the difference in total costs by the difference in the chosen measure of health outcome or effect.[(Cost of intervention A -Cost of Intervention B) / (Effectiveness of Intervention A – Effectiveness of Intervention B)]The result is a ratio of extra cost per extra unit of health effect of a more vs less expensive treatment which can then be measured in QALYs.Again, this is worthy of its own post because there are all kinds of ethical issues around things like how we value life, how we define “healthy” and the ethics of determining whether or not prolonging someone's life is “cost effective.” I'm not going to do a deep dive into that today, but I do want to note that it is a serious issue in these kinds of calculations.In this specific case, even if one was to get past the ethical issues, an accurate calculation is impossible to make on both of the measures of the equation.Cost of these drugs varies wildly between countries and sometimes within countries because, for example, Novo Nordisk is a for-profit corporation whose goal is to create as much profit as possible.  Per the WHO request letter, the monthly cost of liraglutide is $126 in Norway and $709 in the US. Semaglutide is $95 per 30 days in Turkey, but $804 per 30 days in US.When it comes to effectiveness of the treatment, again, there is virtually no long-term data. We do know that in Novo Nordisk's own studies, weight is regained rapidly and cardiometabolic benefits are lost when the drugs are discontinued and even when people stay on the drugs, weight loss levels off after about a year, at 68 weeks weight cycling begins, and at 104 weeks (when follow-up ended) weight was trending up. It's possible that these drugs are utterly ineffective over the long-term and/or that the prevalence of long-term side effects renders any treatment effects moot. We simply do not know.I do not think that this is a remotely appropriate basis from which to request that these drugs be declared globally essential by the WHO.Here are the citation breakdowns. These are not deep dives since there are enough issues with the research on a simple surface analysis.Breakdowns of evidence of comparative effectivenessEffects of liraglutide in the treatment of ob*sity: a randomised, double-blind, placebo-controlled study, Astrup et al.)This is a 20-week study funded by Novo Nordisk. It included 564 people on various doses of liraglutide and a placebo group who didn't get the drug and a group on orlistat. There were no more than 90-98 people in each group.The study explains “Participants on liraglutide lost significantly more weight than did those on placebo” by which they meant that those on the highest dose of liraglutide lose about 9.7lbs more than those on the placebo over the 20 weeks.III LEAD studiesThese are four studies that look at liraglutide in combination with other drugs for the treatment of Type 2 Diabetes that also included some information on weight changes. One was 52 weeks, the others were  26, the maximum amount of weight lost was only about 5lbs.   The first [Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU), Marre et al] was a study that looked at the efficacy of adding liraglutide or rosiglitazone 4 to glimiperide in subjects with Type 2 Diabetes to test effects on blood sugar and body size.The study followed 1041 adults for 26 weeks. The study found that those on .6mg of liraglutide gained 0.7kg, those on 1.2mg gained 0.3kg, and those on 1.8mg of liraglutide lost 0.2kg, while those on placebo lost 0.1kg.The second [Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care, 2009. 32(1): p. 84-90. Nauck, M., et al.,]looked at the efficacy of adding liraglutide to metformin therapy for those with Type 2 Diabetes. They found that over the 26-week study those on liraglutide lost 1.8 ± 0.2, 2.6 ± 0.2, and 2.8 ± 0.2 kg for 0.6, 1.2, and 1.8 mg doses. Those on placebo lost 1.5 ± 0.3kg.The third [Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet, 2009. 373(9662): p. 473-81. Garber, A., et al.,] This was a study of the comparative effectiveness of Liraglutide versus glimepiride for type 2 diabetes, with small weight loss as an ancillary finding. Those in the liraglutide group lost an average of 2kg.The final study [Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD), Zinman et al.]  was a 26-week study with 533 total subjects. The goal was to study the efficacy of liraglutide when added to metformin and rosiglitazone for people with type 2 diabetes. They found that those on liraglutide lost between 0.7 and 2.3kg (1.5lbs to 5.1lbs) in 26 weeks.Meta-Analyses and Systematic Review FindingsEfficacy of Liraglutide in Non-Diabetic Ob*se Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Barboza, J.J., et al., None of the included studies were more than 56 weeks and one was only 14 weeks. One had as many as 3731 subjects, but one had only 40. Some had body weight loss as a primary outcome, but some did not. Maximum doses ranged from 1.8 to 3.0mg. The mean body weight reduction was  3.35 kg (7.4lbs) but in one study there was no difference in weight loss. The maximum difference was 6.3kg (13.9lbs)They also refer to Iqbal et al which we discussed in part 2.Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Vilsbøll, T., et al.The included studies are between 20 and 53 weeks long, and include some of the studies they already cited individually above. Of the 25 included studies only 3 had “ob*sity” as the main inclusion criteria, the rest were Type 2 Diabetes.The mean weight loss for those on the highest dose of the drug was between 0.2kg and 7.2kg. For those in the control group it was 2.9 kg, so there was actually overlap between the treatment and placebo groups.Summary of evidence of safety and harmsThey begin with the claim “The safety profile of GLP-1 receptor agonists is also well studied”To support this they cite: Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Ob*se with or without Diabetes: A Systematic Review and Meta-Analysis, Konwar, M., et al.,This included 14 total studies, many of which the authors of the WHO request had cited individually and were included in other systematic reviews and meta-analyses above. The smallest study included 19 people, the largest included 2,487. The total number of subjects was 4,142.Their conclusion was “Liraglutide in 3.0 mg subcutaneous dose demonstrated significant weight reduction with a reasonable safety profile for patients with overweight or ob*sity regardless of diabetic status compared to placebo.”Their methodology says that they omitted studies from analysis due to “short duration.” They included studies that had a minimum of 12 weeks and a maximum of 56 weeks of follow-up.While they included 14 studies, only 11 of them actually included information about adverse events.In terms of adverse effects (AEs,) they found that the pooled estimate of nine studies in nondiabetic patients and two studies in diabetic patients revealed a significant proportion of patients experiencing the adverse events in liraglutide 3.0 mg group when compared with placebo., and the pooled estimate of the eleven studies showed that liraglutide 3.0 mg had higher risk of AEs compared to placebo.When it came to “serious adverse events” they found that there was a similar risk level between the drug and placebo groups, but remember that's for only 12 to 56 weeks, and Novo Nordisk is recommending that people take these drugs for the rest of their lives. A few months to a little over a year is not enough time to capture long-term serious adverse events.The efficacy and safety of liraglutide in the ob*se, non-diabetic individuals: a systematic review and meta-analysis. Zhang, P., et al.,This included five RCTs (which were included in various of the above systemic reviews and meta-analyses) ranging in follow-up from 14 to 56 weeks.The only adverse event information captured was the number of people who withdrew from treatment due to adverse events (which they found was similar between drug and placebo) and nausea (which was experienced more by people on the drug.)So, in addition to being short in duration, this was far from a comprehensive list of side effects. They made no attempt to capture serious adverse side effects and their short-term nature would have made this difficult anyway.Association of Pharmacological Treatments for Ob*sity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. Khera, R., et al.This looked at weight loss and adverse events with a number of different weight loss drugs. Interestingly liraglutide did not show the highest amount of weight loss but was associated with the highest odds of adverse event–related treatment discontinuation. It should also be noted that high drop-out rates of 30-45% plagued all of the trials which the study authors admit means that “studies were considered to be at high risk of bias.“Given that those who drafted the WHO request are asking that these drugs be considered essential globally, it is disappointing that they included this study and didn't bother to mention this issue in their written request.This included 28 RCTs (most of which were included in other citations above) and only 3 that included liraglutide. They didn't capture individual adverse events, but only “Discontinuation of Therapy Due to Adverse Events.” They only evaluated a year of data so, again, while it is likely that these studies would have captured common adverse events had they bothered to try, there isn't long enough follow-up to have any information about serious (possibly life-threatening) long-term adverse events.Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Ob*sity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis. Vosoughi, K., et al.,This study included 64 RCTs with durations from 12 to 160 weeks, with a median of 26 weeks. As is common in these studies, the majority of the sample (74.9%) was white.Like those above, they only looked at treatment discontinuation from adverse events, they did not capture specific adverse events (common or serious.) Of the seven GLP-1 drugs they tested, liraglutide was tied with taspoglutide for the highest discontinuation of treatment due to adverse events.The study authors also note that “Risk of bias was high or unclear for random sequence generation (29.7%), allocation concealment (26.6%), and incomplete outcome data (26.6%).”Breakdowns for Comparative Cost-effectiveness StudiesFirst, the WHO request authors themselves admit that when it comes to cost-effectiveness, “the analyses have generally been performed only for high-income countries.” This is significant since they are asking the WHO to consider these drugs essential for the entire world.It's also important to understand that none of the data looks at a comparison of cost effectiveness for weight-neutral health interventions to these drugs. Without that information there is no way to calculate actual “cost effectiveness” since it's possible that weight-neutral health interventions would have greater benefits with less risk and dramatically lower cost.  NICE's guidance:  Liraglutide for managing overweight and ob*sity Technology appraisal guidance [TA664]Published: 09 December 2020.Do recall that NICE is involved in the current scandal with Novo Nordisk for influence peddling.These guidelines are created based on a submission of evidence by Novo Nordisk. The committee's understanding of “clinical need” was based on the testimony of a single “patient expert” who “explained that living with ob*sity is challenging and restrictive. There is stigma associated with being ob*se.”Once again we see a rush to blame body size for any “challenges” and “restrictions” of living in a higher-weight body, accompanied by the immediate decision that those bodies should be subjected to healthcare interventions that risk their lives and quality of life in order to be made (temporarily, by Novo and NICE's own admission) thinner.  There did not seem to be a patient expert to discuss the weight-neutral options.It was not immediately apparent if the patient expert was provided/paid by Novo Nordisk, but they certainly forwarded their narrative that simply living in a higher-weight body is a disease requiring treatment.It should be noted that while the trial Novo Nordisk submitted covered a wider range of people, they specifically submitted for this recommendation only the subgroup of that population who were diagnosed with “ob*sity,”  pre-diabetes, and a “high risk of cardiovascular disease based on risk factors such as hypertension and dyslipidaemia.”So, even if we accept this guidance as true, the WHO Essential Medicines request applies to a population much wider than this and so this fails to justify the cost-effectiveness for that population.This guidance is also based on the costs associated with obtaining the drugs through a “specialist weight management service” since an agreement is in place for Novo Nordisk to give a discount to these services.In calculating the ICER per QALY gained, the recommendations note that “Because of the uncertainties in the modelling assumptions, particularly what happens after stopping liraglutide and the calculation of long-term benefits, the committee agreed that an acceptable ICER would not be higher than £20,000 per QALY gained”Again, this recommendation is based on a trial submitted by Novo Nordisk that included 3,721 people and lasted for three years, but only 800 met the criteria for this cost-effectiveness recommendation. The trial failed to show a significant reduction in cardiovascular events. Novo's calculation of risk reduction was based on surrogate outcomes, which NICE points out “introduces uncertainty because causal inference requires direct evidence that liraglutide reduces cardiovascular events. This was not provided in the company submission because of lack of long-term evidence.”The NICE committee admits “relying on surrogates is uncertain but accepted that surrogate outcomes were the only available evidence to estimate cardiovascular benefits.”I just want to point out that another option would be to refuse to experiment on higher-weight people without appropriate evidence.These cost-effectiveness calculations are based on someone using the drug for two years, with no actual data on reduction in cardiovascular events, and with the admitted assumption that “any weight loss returned to the base weight 3 years after treatment discontinuation.” Said another way, this committee decided that it was cost effective to spend up to £20,000 per QALY for people to take a weight loss drug with significant side effects for two years, with no direct evidence of reduced cardiovascular events, and with the acknowledgment that people will be gaining all of their weight back when they stop taking it.Those who wrote the request for WHO to consider these drugs “essential” chose to characterize this as “At the chosen threshold of £20,000 per quality-adjusted life year (QALY) gained, the report concluded that liraglutide is cost-effective for the management of ob*sity.” I do not think that is an accurate characterization of the findings.The request cites “A report by the Canadian Agency for Drugs and Technologies in Health (CADTH) found that compared to standard care, the ICER for liraglutide was $196,876 per QALY gained”For the US, they cite a study that found that to achieve ICERs between $100,000 and $150,000 perQALY or evLY gained, the health-benefit price benchmark range for semaglutide was estimated as $7500 - $9800 per year, which would require a discount of 28-45% from the current US net price.They also cite “Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and ob*sity in the United States, Kim et al.Let's take a look at their conflict of interest disclosure (emphasis mine)“Financial support for this research was provided by Novo Nordisk Inc. The study sponsor [that means Novo Nordisk] was involved in several aspects of the research, including the study design, the interpretation of data, the writing of the manuscript, and the decision to submit the manuscript for publication.Dr Kim and Ms Ramasamy are employees of Novo Nordisk Inc. Ms Kumar and Dr Burudpakdee were employees of Novo Nordisk Inc at the time this study was conducted. Dr Sullivan received research support from Novo Nordisk Inc for this study. Drs Wang, Song, Wu, Ms Xie, and Ms Sun are employees of Analysis Group, Inc, who received consultancy fees from Novo Nordisk Inc in connection with this study.”Given that, you probably won't be shocked to learn that this concluded that Novo Nordisk's drug, semaglutide, was cost-effective. The reason I bolded the text above is that this study is based on modeling – they are taking what is, by their own admission, a “new drug” and making predictions for 30 years. Everything was simulated based on trial data (you know, those trials that we've been discussing that often have horrendous methodology…) and “other relevant literature.” The construction of the modeling and the interpretation of the results was directed by the company who stands to benefit financially from the findings, and carried out by that company's employees and consultants.  Also, and I'll just quote again here since I don't think I can improve on their text “Cost-effectiveness was examined with a willingness-to-pay (WTP) threshold of $150,000 per QALY gained” I do not think that this WTP is based on a global assessment.In their (and by their I mean Novo Nordisk's) modeling they find that semaglutide was estimated to improve QALYs by 0.138 to 0.925 and incur higher costs by $3,254 to $25,086 over the 30-year time horizon vs comparators.And, again, this is without any kind of actual long-term data. I think that the best way to characterize this information is “back of the envelope calculations” at best.To sum up, I do not think that the research they cite comes anywhere close to proving that these drugs have levels of efficacy, safety, or cost-effectiveness that warrant their addition to the WHO list of essential medicines. I believe that if the WHO grants this request I think it will be an affront to medical science, it will cheapen the concept of “essential medicines,” and it will harm untold numbers of higher-weight people all over the world.Did you find this post helpful? You can subscribe for free to get future posts delivered direct to your inbox, or choose a paid subscription to support the newsletter and get special benefits! Click the Subscribe button below for details:Liked this piece? Share this piece:More research and resources:https://haeshealthsheets.com/resources/*Note on language: I use “fat” as a neutral descriptor as used by the fat activist community, I use “ob*se” and “overw*ight” to acknowledge that these are terms that were created to medicalize and pathologize fat bodies, with roots in racism and specifically anti-Blackness. Please read Sabrina Strings' Fearing the Black Body – the Racial Origins of Fat Phobia and Da'Shaun Harrison's Belly of the Beast: The Politics of Anti-Fatness as Anti-Blackness for more on this. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Join Tim and Kim as they talk with Dr. Sarah Klopatek of UC Davis and learn all the chewy bits of her recent comprehensive study on grass-fed beef economics, meat quality, and environmental impacts. BibliographyDavis, H., Magistrali, A., Butler, G., & Stergiadis, S. (2022). Nutritional Benefits from Fatty Acids in Organic and Grass-Fed Beef. Foods, 11(5), 646. https://doi.org/10.3390/foods11050646Geiker, N. R. W., Bertram, H. C., Mejborn, H., Dragsted, L. O., Kristensen, L., Carrascal, J. R., Bügel, S., & Astrup, A. (2021). Meat and Human Health—Current Knowledge and Research Gaps. Foods, 10(7), 1556. https://doi.org/10.3390/foods10071556Klopatek, S. C., Marvinney, E., Duarte, T., Kendall, A., Yang, X. (Crystal), & Oltjen, J. W. (2022a). Grass-fed vs. grain-fed beef systems: Performance, economic, and environmental trade-offs. Journal of Animal Science, 100(2), skab374. https://doi.org/10.1093/jas/skab374Klopatek, S. C., Marvinney, E., Duarte, T., Kendall, A., Yang, X. (Crystal), & Oltjen, J. W. (2022b). Grass-fed vs. grain-fed beef systems: Performance, economic, and environmental trade-offs. Journal of Animal Science, 100(2), skab374. https://doi.org/10.1093/jas/skab374Klopatek, S. C., & Oltjen, J. W. (2022). How advances in animal efficiency and management have affected beef cattle's water intensity in the United States: 1991 compared to 2019. Journal of Animal Science, skac297. https://doi.org/10.1093/jas/skac297Provenza, F. D., Kronberg, S. L., & Gregorini, P. (2019). Is Grassfed Meat and Dairy Better for Human and Environmental Health? Frontiers in Nutrition, 6, 26. https://doi.org/10.3389/fnut.2019.00026Tichenor, N. E., Peters, C. J., Norris, G. A., Thoma, G., & Griffin, T. S. (2017). Life cycle environmental consequences of grass-fed and dairy beef production systems in the Northeastern United States. Journal of Cleaner Production, 142, 1619–1628. https://doi.org/10.1016/j.jclepro.2016.11.138Turner, T. D., Jensen, J., Pilfold, J. L., Prema, D., Donkor, K. K., Cinel, B., Thompson, D. J., Dugan, M. E. R., & Church, J. S. (2015). Comparison of fatty acids in beef tissues from conventional, organic and natural feeding systems in western Canada. Canadian Journal of Animal Science, 95(1), 49–58. https://doi.org/10.4141/cjas-2014-113

Hva mener klimaminister Espen Barth Eide om havvind? Og hvordan vil energipolitisk talsperson i Høyre, Nikolai Astrup, nå Norges klimamål? Har solenergi og kjernekraft en plass i norsk energimiks? Dette er noen av spørsmålene i samtalen mellom Barth Eide og Astrup.

Morten Astrup er grunnlegger av Storm Capital Management og en kjent investor innen obligasjoner, aksjer, eiendom om reiseliv. I denne episoden forteller Morten om hvilke investeringer han har truffet på i 2021, og hvilke planer han har for selskapene sine fremover. Da starter vi episoden!AnnonsørQuartr er den nye måten å gjøre reserach på selskaper. Deres første oppdrag er å gi tilgang til konferansesamtaler, investorpresentasjoner, og inntjeningsrapporter så friksjonsfri som mulig - rett i lommen. Deres andre oppdrag er å skape en helt ny måte for selskaper å nå sine investorer på, og omvendt - å endre måten folk ser på Investor Relations. Deres første kjerneprodukt er nå tilgjengelig for både iOS og Android, og følg med for flere funksjoner i løpet av det kommende året. Quartr er 100% gratis. De inkluderer selskaper fra 12 markeder i dag, og planlegger å legge til flere i løpet av året.Last ned appen her, og følg de på Twitter her.Håper du liker episoden. Hvis du har tid og lyst setter vi stor pris på om du deler episoden med nettverket ditt.Christopher kan nås på twitter gjennom @chrisvonheim.Support me on PatreonOver the last years we have tried to give our community the best possible content on business, investing and entrepreneurship. If you have enjoyed this free content over time and find it valuable, it would be amazing if you want to support us in making more in the future.  See acast.com/privacy for privacy and opt-out information.

Morten Astrup er grunnlegger av Storm Capital Management og en kjent investor innen obligasjoner, aksjer, eiendom om reiseliv. I denne episoden forteller Morten om hvilke investeringer han har truffet på i 2021, og hvilke planer han har for selskapene sine fremover. Da starter vi episoden! AnnonsørQuartr er den nye måten å gjøre reserach på selskaper. Deres første oppdrag er å gi tilgang til konferansesamtaler, investorpresentasjoner, og inntjeningsrapporter så friksjonsfri som mulig - rett i lommen. Deres andre oppdrag er å skape en helt ny måte for selskaper å nå sine investorer på, og omvendt - å endre måten folk ser på Investor Relations. Deres første kjerneprodukt er nå tilgjengelig for både iOS og Android, og følg med for flere funksjoner i løpet av det kommende året. Quartr er 100% gratis. De inkluderer selskaper fra 12 markeder i dag, og planlegger å legge til flere i løpet av året.Last ned appen her, og følg de på Twitter her.Håper du liker episoden. Hvis du har tid og lyst setter vi stor pris på om du deler episoden med nettverket ditt.Christopher kan nås på twitter gjennom @chrisvonheim.Support me on PatreonOver the last years we have tried to give our community the best possible content on business, investing and entrepreneurship. If you have enjoyed this free content over time and find it valuable, it would be amazing if you want to support us in making more in the future.  See acast.com/privacy for privacy and opt-out information.

In this episode of "Let's Talk Farm to Fork", we're joined by Elle Astrup from Foods That Love You Back, who we will be talking to about how their AgTech microgreens farm enables them to grow sustainably exceptional produce every week, all year round using 95% less water and no nasty chemicals.https://foodsthatloveyouback.com/

Today's episode features Danish doubles ace and good friend of mine, Kim Astrup! This is one of the few guest episodes actually recorded sitting right across each other, so please excuse us for the little bit of background noise for a few very short sections of the interview. We mainly focused our chat on the Tokyo Olympics and on getting a deeper understanding of Kim's (and his doubles partner Anders Skaarup Rasmussen) mentality on court, but we touched on several other topics as well. We obviously also had to pay tribute to the legend Markis Kido, who sadly passed away at age 36 on June 14th. Below is a short rundown of the different main topics during our talk: 2.45-7.15 Tribute to Markis Kido. 7.15-19.45 Tokyo Olympics, preparations, expectations, goals and what Mathias Boe has taught him. 19.45-38.00 Being controlled by your emotions, dealing with pressure and expectations from yourself and others and why finding the right mindset every single time is so tricky. 38.00-41.30 Modelling tips from the main model of the Danish team & how Kim suddenly realized he's now one of the old guys! 41.30-43.35 Tips for left/right handed combinations. 43.35-48.10 Kim and Anders' relationship, future and why he's calling Anders Badminton's Benjamin Buttons! 48.10-49.50 How much training is done with and without your partner as a doubles pairing. Hope you all enjoy the episode! And please consider becoming a patron on www.patreon.com/vittinghus to support the podcast and get benefits like early access, personal shout outs and chances to win prizes each month!

Norwegian underwater cinematographer Kjetil C Astrup tells host Brett Stanley about how he first found his path in underwater camera operating, and how he found himself on the set of the latest James Bond film - No Time To Die.Kjetil talks about learning to dive in the Red Sea, and then taking those skills back to the freezing waters of his native Norway. He outlines some of the projects hes worked on, from small personal work and music videos, to feature films and television.Discuss the episode in our facebook group.Follow Kjetil's work here: Website, Instagram, and IMDBSubscribe to www.theunderwaterpodcast.com Support the show (https://www.buymeacoffee.com/brettstanley)